首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Therapeutic Innovation & Regulatory Science

Therapeutic Innovation & Regulatory Science杂志,由Springer International Publishing出版,于1997年创刊,6 issues per year,出版语言English,ISSN:2168-4790,E-ISSN:2168-4804。

投稿咨询
Therapeutic Innovation & Regulatory Science
Therapeutic Innovation & Regulatory Science
Therapeutic Innovation & Regulatory Science
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
4区
影响因子
2.1
CiteScore
4.3
期刊收录
SCI、SCIE

Therapeutic Innovation & Regulatory Science(中文译名:《治疗创新与监管科学》),ISSN:2168-4790,EISSN:2168-4804,是Springer International Publishing出版的国际性学术期刊,创刊于1997年,以6 issues per year形式稳定发行,2026年总发文量约151篇。该刊采用非OA开放访问,学科归属为MEDICAL INFORMATICS - PHARMACOLOGY & PHARMACY。该刊是医学、医学信息领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.1,2025年期刊CiteScore为4.3,2025年期刊自引率约9.5%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Therapeutic Innovation & Regulatory Science长期聚焦医学、医学信息及相关产业的技术应用前沿,在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、医学信息领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Japan、Switzerland、GERMANY (FED REP GER)、Belgium、France等为核心发文国家与地区;US FOOD & DRUG ADMINISTRATION (FDA)ELI LILLY、ABBVIE、PFIZER、NOVARTIS、JOHNSON & JOHNSON、MERCK & COMPANY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
MEDICAL INFORMATICS 医学:信息 PHARMACOLOGY & PHARMACY 药学
4区 3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
MEDICAL INFORMATICS 医学:信息 PHARMACOLOGY & PHARMACY 药学
4区 4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
MEDICAL INFORMATICS 医学:信息 PHARMACOLOGY & PHARMACY 药学
4区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:MEDICAL INFORMATICS SCIE Q4 46 / 54

15.7

学科:PHARMACOLOGY & PHARMACY SCIE Q3 240 / 356

32.7

学科:MEDICAL INFORMATICS SCIE Q4 48 / 55

13.64

学科:PHARMACOLOGY & PHARMACY SCIE Q3 252 / 356

29.35

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:MEDICAL INFORMATICS SCIE Q4 36 / 44

19.3

学科:PHARMACOLOGY & PHARMACY SCIE Q3 222 / 354

37.4

学科:MEDICAL INFORMATICS SCIE Q4 41 / 44

7.95

学科:PHARMACOLOGY & PHARMACY SCIE Q4 276 / 354

22.18


中国学者近期发文

1
Adverse Events Associated with Clascoterone: A Real-World Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting Syste

Author:Tao, Li; Zhang, Mengying; Zhang, Wenyue; Feng, Peishi; Zhou, Min; Wang, Ping

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-026-00968-2

2
Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontier

Author:Rao, Yanmei; Dong, Li; Huang, Zhe

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-025-00913-9

3
Applications and Challenges of Artificial Intelligence and Big Data in Drug Regulatio

Author:Liu, Zhao; Zheng, Yang; Fang, Jun; Yuan, Lin

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-026-00946-8

4
Ethical Challenges and Considerations in Decentralized Clinical Trials (DCTs): Insights from a Scoping Revie

Author:Han, Lijia; Ooi, Kai Hong; Balakrishnan, Krisna Veni; Phan, Chia Wei

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-026-00949-5

5
Research on the Quality Evaluation Indicators of Real-World Data in the Review of Anti-Tumor Drugs for Chinese Regulatory Framework

Author:Zhang, Jie-ying; Tang, Yong; Dong, Fang-zheng; Mao, Ning-ying; Li, Jun

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-026-00943-x

6
Application of Artificial Intelligence in MedDRA Coding: A Practical Exploration from Clinical Data Management Perspectiv

Author:Yan, Charles; Yang, Ruier; Yan, Huaihai; Wei, Xin; Zhou, Erkang; Zhao, Shouzhu; Zhuang, Yonglong

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-026-00953-9

7
Patent Analysis Perspectives on China's Orphan Drug R&D: Status and Technology Characteristic

Author:Jiao, Yang; Yuan, Fangzhe; Liu, Tianyu; Han, Jiajia; Sun, Jingchun; Chu, Shuzhen; Li, Shuxiang

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s43441-026-00927-x

8
Advancing AI Ethics Frameworks in Drug Development: Global Applicability, Practical Challenges, and Dynamic Governanc

Author:Chen, Kai; Yu, Zekai

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s43441-025-00814-x

9
Changes in Clinical Trials of Dermatological Drugs in Mainland China Between 2016 and 2022: A Narrative Revie

Author:Zhu, Beibei; Li, Jing; Ni, Qi; Yang, Shuo; Yin, Zheng; Yang, Xueyuan

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s43441-025-00743-9

10
Basic Considerations for the Consistency Evaluation Based on ICH E17 Guidelin

Author:Long, Meihua; Wu, Haiyan; Liu, Xiaoni; Li, Pengfei; Lin, Renxin; Zhao, Ziwei; Kou, Xiujing; Zhu, Chao; Ji, Chen; Zhang, Wei; Zhang, Kezhou; Yu, Bing; Wang, Yun; Zhang, Hua; Jia, Fan; Hou, Yan

Journal: THERAPEUTIC INNOVATION & REGULATORY SCIENCE. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s43441-024-00737-z


在线咨询

Therapeutic Innovation & Regulatory Science

国际简称:THER INNOV REGUL SCI参考译名:治疗创新与监管科学

年发文量:151 CiteScore:4.3 是否预警:否 Gold OA文章占比:46.65% 研究类文章占比:76.82%

杂志社联系方式:TIERGARTENSTRASSE 17, HEIDELBERG, GERMANY, D-69121

Therapeutic Innovation & Regulatory Science